{"id":"W4414800255","doi":"10.1093/neuonc/noaf193.522","title":"P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Randomized controlled trial; Clinical endpoint; Discontinuation; Quality of life (healthcare); Radiation therapy; Placebo; Chemoradiotherapy; Maintenance therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01211465,0.003682908,0.004236443,0.001117391,0.00213695,0.002037437,0.003322579,0.004998873,0.05371204],"category_scores_gemma":[0.007511498,0.002096558,0.002432575,0.00131295,0.002303587,0.001998799,0.001061535,0.006161097,0.01358293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002445811,"about_ca_system_score_gemma":0.01034925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001616574,"about_ca_topic_score_gemma":0.004272379,"domain_scores_codex":[0.9951758,0.002746496,0.0003499499,0.0006554287,0.000415277,0.0006570728],"domain_scores_gemma":[0.9961075,0.0005572709,0.0008052323,0.0005210546,0.0006380217,0.001370877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9442604,0.01289877,0.0004640078,0.00352633,0.0003937432,0.0001156468,0.0001358742,0.0005957366,0.004309713,0.001612583,0.01583543,0.01585167],"study_design_scores_gemma":[0.9534031,0.02690184,0.0007220535,0.0003440129,0.0001830229,0.00005022739,0.00002618552,0.0004270492,0.0006777233,0.000644366,0.01659191,0.00002847811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.02309226,0.001274889,0.002912472,0.0008317094,0.0009127696,0.957148,0.00812004,0.0003379887,0.005369937],"genre_scores_gemma":[0.0244622,0.0007816172,0.005252933,0.001090924,0.0002569962,0.9616823,0.002388878,0.00004082493,0.004043378],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05371204,"threshold_uncertainty_score":0.1796847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04164772387309838,"score_gpt":0.4207072218484051,"score_spread":0.3790594979753067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}